Results
1 -
5 of
5The kinase inhibitors R406 and GS-9973 impair T cell functions and macrophage-mediated anti-tumor activity of rituximab in chronic lymphocytic leukemia patients, Cancer Immunology, Immunotherapy Inhibition of ovarian tumor cell invasiveness by targeting SYK in the tyrosine kinase signaling pathway, Oncogene Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers, Clinical Drug Investigation Syk inhibitors in clinical development for hematological malignancies, Journal of Hematology & Oncology